TY - JOUR
T1 - Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer
T2 - The role of anthracycline dose intensity
AU - Bozzetti, Cecilia
AU - Musolino, Antonino
AU - Camisa, Roberta
AU - Bisagni, Giancarlo
AU - Flora, Marcella
AU - Bassano, Cristina
AU - Martella, Eugenia
AU - Lagrasta, Costanza
AU - Nizzoli, Rita
AU - Personeni, Nicola
AU - Leonardi, Francesco
AU - Cocconi, Giorgio
AU - Ardizzoni, Andrea
PY - 2006/4
Y1 - 2006/4
N2 - OBJECTIVES: The value of HER-2/neu status as a predictor of response to anthracycline-based chemotherapy is still a matter of debate. We evaluated the contribution of HER-2/neu gene amplification and other biologic markers in predicting response to different doses of neoadjuvant anthracycline-based chemotherapy. METHODS: Clinical and pathologic records of 115 primary breast cancer patients were reviewed. Forty-eight and 67 patients received high (doxorubicin ≥20 mg/m/wk; epirubicin ≥30 mg/m/wk) and moderate-low anthracycline dose intensity regimens, respectively. Pathologic diagnosis, hormonal receptor status (HR), Ki67, and HER-2/neu status were assessed on tumor samples before neoadjuvant chemotherapy. HER-2/neu was determined by fluorescence in situ hybridization (FISH). RESULTS: HER-2/neu amplification was observed in 29/115 (25%) tumors, 18 from moderate-low-dose and 11 from high-dose group. In the univariate analysis, a high Ki67 index (≥20%) and positive clinical axillary nodes were predictive of an objective tumor response (P = 0.033 and 0.001, respectively). In the multivariate analysis, Ki67 was the only factor predictive of response (OR = 3.08, 95% CI = 1.1-8.5, P = 0.03). HER-2/neu status was not a factor in predicting objective response to different anthracycline dose intensities. The same finding was observed with regards to HR and Ki67. CONCLUSIONS: In our series, no significant dose-response relationship was found according to HER-2/neu status.
AB - OBJECTIVES: The value of HER-2/neu status as a predictor of response to anthracycline-based chemotherapy is still a matter of debate. We evaluated the contribution of HER-2/neu gene amplification and other biologic markers in predicting response to different doses of neoadjuvant anthracycline-based chemotherapy. METHODS: Clinical and pathologic records of 115 primary breast cancer patients were reviewed. Forty-eight and 67 patients received high (doxorubicin ≥20 mg/m/wk; epirubicin ≥30 mg/m/wk) and moderate-low anthracycline dose intensity regimens, respectively. Pathologic diagnosis, hormonal receptor status (HR), Ki67, and HER-2/neu status were assessed on tumor samples before neoadjuvant chemotherapy. HER-2/neu was determined by fluorescence in situ hybridization (FISH). RESULTS: HER-2/neu amplification was observed in 29/115 (25%) tumors, 18 from moderate-low-dose and 11 from high-dose group. In the univariate analysis, a high Ki67 index (≥20%) and positive clinical axillary nodes were predictive of an objective tumor response (P = 0.033 and 0.001, respectively). In the multivariate analysis, Ki67 was the only factor predictive of response (OR = 3.08, 95% CI = 1.1-8.5, P = 0.03). HER-2/neu status was not a factor in predicting objective response to different anthracycline dose intensities. The same finding was observed with regards to HR and Ki67. CONCLUSIONS: In our series, no significant dose-response relationship was found according to HER-2/neu status.
KW - Anthracyclines
KW - Breast cancer
KW - HER-2/neu
KW - Neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=33645779551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645779551&partnerID=8YFLogxK
U2 - 10.1097/01.coc.0000204405.96572.f9
DO - 10.1097/01.coc.0000204405.96572.f9
M3 - Article
C2 - 16601438
AN - SCOPUS:33645779551
VL - 29
SP - 171
EP - 177
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 2
ER -